Strategic Partners A/S

Corporate Details

ISIN(s):

DK0062502894 (+1 more)

LEI:

54930025OZD2GGSQ7L42

Country:

Denmark

Address:

Lyskær 8 A st. tv., 2730 Herlev

Website:

https://www.orphazyme.com/

Sector:

Professional, scientific and technical activities

Industry:

Research and experimental development on natural sciences and engineering

Description

Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature. We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC). In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.